The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases

Paul W. Sperduto; Wen Jiang; Paul D. Brown; Steve Braunstein; Penny Sneed; Daniel A. Wattson; Helen A. Shih; Ananta Bangdiwala; Ryan Shanley; Natalie A. Lockney; Kathryn Beal; Emil Lou; Thomas Amatruda; William A. Sperduto; John P. Kirkpatrick; Norman Yeh; Laurie E. Gaspar; Jason K. Molitoris; Laura Masucci; David Roberge; James Yu; Veronica Chiang; Minesh Mehta

doi:10.1016/j.ijrobp.2017.03.030

The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases

Paul W. Sperduto, Wen Jiang, Paul D. Brown, Steve Braunstein, Penny Sneed, Daniel A. Wattson, Helen A. Shih, Ananta Bangdiwala, Ryan Shanley, Natalie A. Lockney, Kathryn Beal, Emil Lou, Thomas Amatruda, William A. Sperduto, John P. Kirkpatrick, Norman Yeh, Laurie E. Gaspar, Jason K. Molitoris, Laura Masucci, David RobergeJames Yu, Veronica Chiang, Minesh Mehta

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	International Journal of Radiation Oncology Biology Physics
Volume	98
DOIs	https://doi.org/10.1016/j.ijrobp.2017.03.030
State	Published - Jan 8 2017

Disciplines

Oncology
Pathology
Surgery

Access to Document

10.1016/j.ijrobp.2017.03.030License: Unspecified

Cite this

Sperduto, P. W., Jiang, W., Brown, P. D., Braunstein, S., Sneed, P., Wattson, D. A., Shih, H. A., Bangdiwala, A., Shanley, R., Lockney, N. A., Beal, K., Lou, E., Amatruda, T., Sperduto, W. A., Kirkpatrick, J. P., Yeh, N., Gaspar, L. E., Molitoris, J. K., Masucci, L., ... Mehta, M. (2017). The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases. International Journal of Radiation Oncology Biology Physics, 98. https://doi.org/10.1016/j.ijrobp.2017.03.030

Sperduto, PW, Jiang, W, Brown, PD, Braunstein, S, Sneed, P, Wattson, DA, Shih, HA, Bangdiwala, A, Shanley, R, Lockney, NA, Beal, K, Lou, E, Amatruda, T, Sperduto, WA, Kirkpatrick, JP, Yeh, N, Gaspar, LE, Molitoris, JK, Masucci, L, Roberge, D, Yu, J, Chiang, V & Mehta, M 2017, 'The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases', International Journal of Radiation Oncology Biology Physics, vol. 98. https://doi.org/10.1016/j.ijrobp.2017.03.030

@article{5d89010358574f539608d34137049224,

title = "The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases",

author = "Sperduto, \{Paul W.\} and Wen Jiang and Brown, \{Paul D.\} and Steve Braunstein and Penny Sneed and Wattson, \{Daniel A.\} and Shih, \{Helen A.\} and Ananta Bangdiwala and Ryan Shanley and Lockney, \{Natalie A.\} and Kathryn Beal and Emil Lou and Thomas Amatruda and Sperduto, \{William A.\} and Kirkpatrick, \{John P.\} and Norman Yeh and Gaspar, \{Laurie E.\} and Molitoris, \{Jason K.\} and Laura Masucci and David Roberge and James Yu and Veronica Chiang and Minesh Mehta",

note = "BRAF status was known in 584 of 823 patients (71\%). BRAF, NRAS, and C-KIT mutations were present in 51\%, 22\%, and 11\% of tested patients, respectively. The median time from primary diagnosis to brain metastasis was 32 months, and overall median survival (MS) from the time of initial treatment of brain metastases was 10 months.",

year = "2017",

month = jan,

day = "8",

doi = "10.1016/j.ijrobp.2017.03.030",

language = "American English",

volume = "98",

journal = "International Journal of Radiation Oncology Biology Physics",

}

TY - JOUR

T1 - The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases

AU - Sperduto, Paul W.

AU - Jiang, Wen

AU - Brown, Paul D.

AU - Braunstein, Steve

AU - Sneed, Penny

AU - Wattson, Daniel A.

AU - Shih, Helen A.

AU - Bangdiwala, Ananta

AU - Shanley, Ryan

AU - Lockney, Natalie A.

AU - Beal, Kathryn

AU - Lou, Emil

AU - Amatruda, Thomas

AU - Sperduto, William A.

AU - Kirkpatrick, John P.

AU - Yeh, Norman

AU - Gaspar, Laurie E.

AU - Molitoris, Jason K.

AU - Masucci, Laura

AU - Roberge, David

AU - Yu, James

AU - Chiang, Veronica

AU - Mehta, Minesh

N1 - BRAF status was known in 584 of 823 patients (71%). BRAF, NRAS, and C-KIT mutations were present in 51%, 22%, and 11% of tested patients, respectively. The median time from primary diagnosis to brain metastasis was 32 months, and overall median survival (MS) from the time of initial treatment of brain metastases was 10 months.

PY - 2017/1/8

Y1 - 2017/1/8

UR - https://www.sciencedirect.com/science/article/pii/S0360301617307216

U2 - 10.1016/j.ijrobp.2017.03.030

DO - 10.1016/j.ijrobp.2017.03.030

M3 - Article

VL - 98

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

ER -

The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases

Disciplines

Access to Document

Other files and links

Cite this